Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

MLO LABline Daily - Feb 24th, 2024

HER2 Positive and Negative Breast Cancers: Aggressiveness, Treatment, and Survival

Oncology

Breast Cancer and Hormone Receptor Positive Status - Moose and Doc

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer, Journal of Experimental & Clinical Cancer Research

A gene expression-based classifier for HER2-low breast cancer

Frontiers Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Table 2 from Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes

Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors - ScienceDirect

How HER2 Evolved As A Companion Diagnostic

A Comprehensive Outline Of Trastuzumab Resistance Biomarkers In HER2 Overexpressing Breast Cancer

Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center - Modern Pathology